<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03177395</url>
  </required_header>
  <id_info>
    <org_study_id>PP100-001</org_study_id>
    <nct_id>NCT03177395</nct_id>
  </id_info>
  <brief_title>PP100-01 (Calmangafodipir) for Overdose of Paracetamol</brief_title>
  <acronym>POP</acronym>
  <official_title>A Randomised Open Label Exploratory, Safety and Tolerability Study With PP100-01 in Patients Treated With the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose (The POP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PledPharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PledPharma AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the safety and tolerability of PP100-01 add-on treatment to the 12hr NAC
      treatment regime in patients treated for paracetamol/acetaminophen overdose (POD) when NAC
      treatment is initiated before 24hours post POD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be an open label, randomised, exploratory, rising dose design, NAC controlled,
      phase 1 safety and tolerability study in patients treated with NAC for
      paracetamol/acetaminophen overdose.

      Entry into the study will depend on the patient's blood results confirming the need for NAC.
      A total of 24 patients will be assigned into one of 3 dosing cohorts of 8 patients (N=6 for
      PP100-01 and NAC; N=2 for NAC alone).

      The study will primarily evaluate safety and tolerability for treatment with PP100-01 in
      combination with NAC as compared to NAC alone.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 8, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Events</measure>
    <time_frame>90 days</time_frame>
    <description>Adverse Events and Serious Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Pulse Rate</measure>
    <time_frame>Baseline</time_frame>
    <description>Pulse rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Pulse rate</measure>
    <time_frame>2 hours</time_frame>
    <description>Pulse rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- pulse rate</measure>
    <time_frame>2.5 hours</time_frame>
    <description>Pulse rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- pulse rate</measure>
    <time_frame>10 hours</time_frame>
    <description>Pulse rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- pulse rate</measure>
    <time_frame>20 hours</time_frame>
    <description>Pulse rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- BP</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- BP</measure>
    <time_frame>2 hours</time_frame>
    <description>Blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- BP</measure>
    <time_frame>2.5 hours</time_frame>
    <description>Blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- BP</measure>
    <time_frame>10 hours</time_frame>
    <description>Blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- BP</measure>
    <time_frame>20 hours</time_frame>
    <description>Blood pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Respiratory rate</measure>
    <time_frame>Baseline</time_frame>
    <description>Respiratory rate (rpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations-Respiratory rate</measure>
    <time_frame>2 hours</time_frame>
    <description>Respiratory rate (rpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Respiratory rate</measure>
    <time_frame>2.5 hours</time_frame>
    <description>Respiratory rate(rpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Respiratory rate</measure>
    <time_frame>10 hours</time_frame>
    <description>Respiratory rate (rpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Respiratory rate</measure>
    <time_frame>20 hours</time_frame>
    <description>Respiratory rate (rpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Pulse Oximetry</measure>
    <time_frame>Baseline</time_frame>
    <description>Pulse oximetry (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Pulse Oximetry</measure>
    <time_frame>2 hours</time_frame>
    <description>Pulse oximetry (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Pulse Oximetry</measure>
    <time_frame>2.5 hours</time_frame>
    <description>Pulse oximetry (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Pulse Oximetry</measure>
    <time_frame>10 hours</time_frame>
    <description>Pulse oximetry (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Pulse Oximetry</measure>
    <time_frame>20 hours</time_frame>
    <description>Pulse oximetry (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Temperature</measure>
    <time_frame>Baseline</time_frame>
    <description>Temperature (Degrees Celsius)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Temperature</measure>
    <time_frame>2 hours</time_frame>
    <description>Temperature (Degrees Celsius)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Temperature</measure>
    <time_frame>2.5 hours</time_frame>
    <description>Temperature (Degrees Celsius)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Temperature</measure>
    <time_frame>10 hours</time_frame>
    <description>Temperature (Degrees Celsius)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Observations- Temperature</measure>
    <time_frame>20 hours</time_frame>
    <description>Temperature (Degrees Celsius)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters- APAP</measure>
    <time_frame>screening</time_frame>
    <description>APAP concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-APAP</measure>
    <time_frame>10 hours</time_frame>
    <description>APAP concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-APAP</measure>
    <time_frame>20 hours</time_frame>
    <description>APAP concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters- INR</measure>
    <time_frame>screening</time_frame>
    <description>INR (no units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters- INR</measure>
    <time_frame>2hours</time_frame>
    <description>INR (no units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters- INR</measure>
    <time_frame>10hours</time_frame>
    <description>INR (no units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters- INR</measure>
    <time_frame>20hours</time_frame>
    <description>INR (no units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters- ALT</measure>
    <time_frame>screening</time_frame>
    <description>ALT (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters- ALT</measure>
    <time_frame>2 hours</time_frame>
    <description>ALT (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-ALT</measure>
    <time_frame>10 hours</time_frame>
    <description>ALT (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-ALT</measure>
    <time_frame>20 hours</time_frame>
    <description>ALT (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-ALP</measure>
    <time_frame>Screening</time_frame>
    <description>ALP (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-ALP</measure>
    <time_frame>2 hours</time_frame>
    <description>ALP (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-ALP</measure>
    <time_frame>10 hours</time_frame>
    <description>ALP (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-ALP</measure>
    <time_frame>20 hours</time_frame>
    <description>ALP (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Bilirubin</measure>
    <time_frame>Screening</time_frame>
    <description>Bilirubin (umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Bilirubin</measure>
    <time_frame>2 hours</time_frame>
    <description>Bilirubin (umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Bilirubin</measure>
    <time_frame>10 hours</time_frame>
    <description>Bilirubin (umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Bilirubin</measure>
    <time_frame>20 hours</time_frame>
    <description>Bilirubin (umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Creatinine</measure>
    <time_frame>Screening</time_frame>
    <description>Creatinine (umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Creatinine</measure>
    <time_frame>2 hours</time_frame>
    <description>Creatinine (umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Creatinine</measure>
    <time_frame>10 hours</time_frame>
    <description>Creatinine (umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Creatinine</measure>
    <time_frame>20hours</time_frame>
    <description>Creatinine (umol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-HB</measure>
    <time_frame>Screening</time_frame>
    <description>Haemoglobin (g/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-HB</measure>
    <time_frame>10 hours</time_frame>
    <description>Haemoglobin (g/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-HB</measure>
    <time_frame>20 hours</time_frame>
    <description>Haemoglobin (g/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Urea</measure>
    <time_frame>Screening</time_frame>
    <description>Urea (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Urea</measure>
    <time_frame>10 hours</time_frame>
    <description>Urea (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Urea</measure>
    <time_frame>20 hours</time_frame>
    <description>Urea (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Na</measure>
    <time_frame>Screening</time_frame>
    <description>Sodium (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Na</measure>
    <time_frame>10 hours</time_frame>
    <description>Sodium (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-Na</measure>
    <time_frame>20 hours</time_frame>
    <description>Sodium (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters- Potassium</measure>
    <time_frame>Screening</time_frame>
    <description>Potassium (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters- Potassium</measure>
    <time_frame>10 hours</time_frame>
    <description>Potassium (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters- Potassium</measure>
    <time_frame>20 hours</time_frame>
    <description>Potassium (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-MCV</measure>
    <time_frame>Screening</time_frame>
    <description>MCV (fL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-MCV</measure>
    <time_frame>10 hours</time_frame>
    <description>MCV (fL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-MCV</measure>
    <time_frame>20 hours</time_frame>
    <description>MCV (fL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-WBC</measure>
    <time_frame>Screening</time_frame>
    <description>WBC (x10*9/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-WBC</measure>
    <time_frame>10 hours</time_frame>
    <description>WBC (x10*9/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and clinical biochemistry parameters-WBC</measure>
    <time_frame>20 hours</time_frame>
    <description>WBC(x10*9/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma-MiR122</measure>
    <time_frame>2hours</time_frame>
    <description>MiR122</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma-MiR122</measure>
    <time_frame>10hours</time_frame>
    <description>MiR122</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma-MiR122</measure>
    <time_frame>20hours</time_frame>
    <description>MiR122</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma-GLDH</measure>
    <time_frame>2hours</time_frame>
    <description>GLDH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma-GLDH</measure>
    <time_frame>10 hours</time_frame>
    <description>GLDH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma-GLDH</measure>
    <time_frame>20 hours</time_frame>
    <description>GLDH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma-mitochondrial DNA</measure>
    <time_frame>2hours</time_frame>
    <description>mitochondrial DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma-mitochondrial DNA</measure>
    <time_frame>10 hours</time_frame>
    <description>mitochondrial DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma-mitochondrial DNA</measure>
    <time_frame>20 hours</time_frame>
    <description>mitochondrial DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma - CK18</measure>
    <time_frame>2 hours</time_frame>
    <description>CK18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma - CK18</measure>
    <time_frame>10 hours</time_frame>
    <description>CK18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma - CK18</measure>
    <time_frame>20 hours</time_frame>
    <description>CK18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma-microRNA</measure>
    <time_frame>2 hours</time_frame>
    <description>microRNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma-microRNA</measure>
    <time_frame>10 hours</time_frame>
    <description>microRNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experimental biomarkers in serum/plasma-microRNA</measure>
    <time_frame>20 hours</time_frame>
    <description>microRNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hepatotoxicity</measure>
    <time_frame>2 hours</time_frame>
    <description>Incidence of hepatotoxicity between 12hr NAC arm and individual PP100-01 + NAC treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hepatotoxicity</measure>
    <time_frame>10 hours</time_frame>
    <description>Incidence of hepatotoxicity between 12hr NAC arm and individual PP100-01 + NAC treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hepatotoxicity</measure>
    <time_frame>20 hours</time_frame>
    <description>Incidence of hepatotoxicity between 12hr NAC arm and individual PP100-01 + NAC treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>90days</time_frame>
    <description>Days for the individual PP100-01 + NAC arms vs 12hr NAC arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Secondary outcome - Hepatotoxicity</measure>
    <time_frame>20hrs</time_frame>
    <description>To determine the rate of occurrence of hepatotoxicity (defined by raised biochemical markers) in patients treated with PP100-01 and 12hr NAC administration regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Secondary outcome - Anaphylactoid reactions</measure>
    <time_frame>20hrs</time_frame>
    <description>To compare the incidence of anaphylactoid reactions in the co-treatment and 12hr NAC regimens in APAP poisoned patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Secondary outcome - occurrence of hepatotoxicity</measure>
    <time_frame>12hr</time_frame>
    <description>To determine the occurrence of hepatotoxicity as determined at the end of the 12hr NAC administration regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Secondary outcome - length of hospital stay</measure>
    <time_frame>90days</time_frame>
    <description>To measure length of hospital stay in patients receiving co-treatment and 12hr NAC treatment regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Secondary outcome - ALT increase</measure>
    <time_frame>10hr</time_frame>
    <description>Proportion of patients with a 50% increase in ALT after 10h post-treatment with NAC, compared with the admission value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Secondary outcome - ALT&gt;100</measure>
    <time_frame>10hr</time_frame>
    <description>Proportion of patients with ALT&gt;100 at 10h post-treatment with NAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Secondary outcome INR&gt;1.3</measure>
    <time_frame>10hr</time_frame>
    <description>Proportion of patients with INR&gt;1.3 at 10h post-treatment with NAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Secondary outcome - APAP concentration &gt;20mg/mL</measure>
    <time_frame>20hrs</time_frame>
    <description>Proportion of patients with paracetamol/acetaminophen (APAP) concentration &gt; 20 mg/mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Paracetamol Overdose</condition>
  <arm_group>
    <arm_group_label>Acetylcysteine (N-acetylcysteine; NAC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PP100-01 (Calmangafodipir)+ NAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:
Group A: PP100-01 (2 umol/kg calmangafodipir) after the &quot;loading&quot; dose of NAC
Group B: PP100-01 (5 umol/kg calmangafodipir) after the &quot;loading&quot; dose of NAC
Group C: PP100-01 (10 umol/kg calmangafodipir) after the &quot;loading&quot; dose of NAC
PP100-01 treatment is administered intravenously over 5 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PP100-01 (calmangafodipir)</intervention_name>
    <description>PP100-01</description>
    <arm_group_label>PP100-01 (Calmangafodipir)+ NAC</arm_group_label>
    <other_name>PP100-01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any patient with capacity admitted to hospital within 24 hrs either a single acute POD
             or more than one dose of paracetamol (staggered) and deemed to require treatment with
             NAC.

          2. Provision of written informed consent

          3. Males and females of at least 16 years of age

        Exclusion Criteria:

          1. Patients that do not have the capacity to consent to participate in the study

          2. Patients detained under the Mental Health Act or deemed unfit by the Investigator to
             participate due to mental health.

          3. Patients with known permanent cognitive impairment

          4. Patients who are pregnant or nursing

          5. Patients who have previously participated in the study

          6. Unreliable history of POD

          7. Patients presenting after 24hrs of POD

          8. Patients who take anticoagulants (e.g. warfarin) therapeutically or have taken an
             overdose of anticoagulants

          9. Patients who, in the opinion of the responsible clinician/nurse, are unlikely to
             complete the full course of NAC e.g. expressing wish to self-discharge

         10. Prisoners

         11. Non-English speaking patients. (Study information material will only be produced in
             English in view of the known and stable demographic of the Edinburgh self-harm
             population).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Dear</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>City of Edinburgh</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug Overdose</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Pyridoxal Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

